Abstract 1685P
Background
Family caregivers play a vital role in cancer care, yet their effective integration, needs assessment, and support in German outpatient settings require further examination. This qualitative study explores family caregivers' experiences, preferences, and integration challenges, employing a unique dyadic approach to analyze patient-caregiver dynamics and incorporating oncologists' perspectives on effective caregiver integration. It also suggests areas of potential integration of innovative technologies to address these challenges.
Methods
The study uses a reflexive thematic analysis of qualitative semi-structured interviews with 15 patient-caregiver dyads involving advanced cancer patients with solid tumours and three oncologists at a German outpatient cancer centre.
Results
Three interconnected themes emerged: 1) The multifaceted impact of illness on patient-caregiver dyads, emphasizing the significance of dyadic support and incongruence; 2) Communication with physicians and understanding of healthcare Information, stressing the need for tailored prognostic communication, and considering health literacy aspects; 3) Navigating healthcare services and psychosocial support, underlining the importance of a regular needs and distress evaluation, providing personalized support in the form of a referral and proactive guidance upon cancer diagnosis.
Conclusions
The study's findings have practical implications for healthcare practice and policy. Healthcare systems should adopt a more caregiver-inclusive approach that provides proactive psychosocial support at the beginning of the cancer journey, and tailored communication with healthcare professionals. This approach could include developing and implementing targeted digital tools that allow automated needs evaluation and incorporation of referrals for specialized support programs for cancer caregivers. The future investigation and implementation of such innovative technologies is important, as they have the potential to reduce the caregiving burden and significantly enhance the overall quality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Rose: Other, Institutional, Leadership Role: Head of Promis National Center Germany. All other authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11